General Information of the Compound
Compound ID
CP0371819
Compound Name
(3S)-3-[(2S)-2-[(2S)-2-{2-[(2R)-2-[(2S)-2-amino-3-(4-hydroxyphenyl)propanamido]-3-phenylpropanamido]acetamido}-3-(1H-indol-3-yl)propanamido]hexanamido]-3-{[(1S)-1-carbamoyl-2-phenylethyl]carbamoyl}propanoic acid
    Show/Hide
Synonyms
(3S)-3-[(2S)-2-[(2S)-2-{2-[(2R)-2-[(2S)-2-amino-3-(4-hydroxyphenyl)propanamido]-3-phenylpropanamido]acetamido}-3-(1H-indol-3-yl)propanamido]hexanamido]-3-{[(1S)-1-carbamoyl-2-phenylethyl]carbamoyl}propanoic acid
BDBM21137
CCK-Opioid Peptide, 7
CHEMBL382051
Tyr-D-Phe-Gly-Trp-Nle-Asp-Phe-NH2
    Show/Hide
Structure
Formula
C50H59N9O10
Molecular Weight
946.075
Canonical SMILES
CCCC[C@H](NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)CNC(=O)[C@@H](Cc1ccccc1)NC(=O)[C@@H](N)Cc1ccc(O)cc1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](Cc1ccccc1)C(N)=O
    Show/Hide
InChI
InChI=1S/C50H59N9O10/c1-2-3-17-38(48(67)59-42(27-44(62)63)50(69)57-39(45(52)64)24-30-12-6-4-7-13-30)56-49(68)41(26-33-28-53-37-18-11-10-16-35(33)37)55-43(61)29-54-47(66)40(25-31-14-8-5-9-15-31)58-46(65)36(51)23-32-19-21-34(60)22-20-32/h4-16,18-22,28,36,38-42,53,60H,2-3,17,23-27,29,51H2,1H3,(H2,52,64)(H,54,66)(H,55,61)(H,56,68)(H,57,69)(H,58,65)(H,59,67)(H,62,63)/t36-,38-,39-,40+,41-,42-/m0/s1
    Show/Hide
InChIKey
DWHRPZRXNRDAQF-GEQJWKGNSA-N
Physicochemical Property
logP
1.1618
Rotatable Bonds
26
Heavy Atom Count
69
Polar Areas
317.03
Hydrogen Bond Donor Count
11
Hydrogen Bond Acceptor Count
10
Complexity
69

"RO5" indicates the cutoff set by lipinski's rule of five:

(1) Molecular weight less than 500 Dalton;

(2) xlogp less than 5;

(3) No more than 5 hbonddonor (Hydrogen Bond Donor Count);

(4) No more than 10 hbondacc (Hydrogen Bond Acceptor Count);

(5) No more than 10 rotbonds (Rotatable Bond Count).

    Show/Hide
Click to Show/Hide the External Link(s) of This Compound
PubChem ID
CID: 11051303
SID: 16116958
ChEMBL ID
CHEMBL382051
Map of Molecular Bioactivity Related to the Compound
Map of Molecular Bioactivity Related to the Compound

Compound
Cell Line
Protein

Bioactivity Value:

<= 0.1 μM
> 0.1 μM and <= 10 μM
> 10 μM
Imprecise Activity
Table of Molecular Bioactivities Related to the Compound
Protein ID: PT00958, Cholecystokinin receptor type A
Cell-based Assay
Cell Line ID Cell Line Name Cell Line Organism
CL000006 HEK293 Homo sapiens (Human)  2
1
IC50 = 97.72 nM
   TI
   LI
   LO
   TS
2
Ki = 98 nM
   TI
   LI
   LO
   TS
Protein ID: PT01200, Delta-type opioid receptor
Cell-based Assay
Cell Line ID Cell Line Name Cell Line Organism
CL000661 HN9.10e Mus musculus (Mouse)  2
1
IC50 = 0.4266 nM
   TI
   LI
   LO
   TS
2
Ki = 0.2 nM
   TI
   LI
   LO
   TS
Protein ID: PT01124, Gastrin/cholecystokinin type B receptor
Cell-based Assay
Cell Line ID Cell Line Name Cell Line Organism
CL000006 HEK293 Homo sapiens (Human)  2
1
IC50 = 25.7 nM
   TI
   LI
   LO
   TS
2
Ki = 26 nM
   TI
   LI
   LO
   TS
Protein ID: PT01549, Mu-type opioid receptor
Cell-based Assay
Cell Line ID Cell Line Name Cell Line Organism
CL000661 HN9.10e Mus musculus (Mouse)  2
1
IC50 = 79.43 nM
   TI
   LI
   LO
   TS
2
Ki = 34 nM
   TI
   LI
   LO
   TS
Clinical Information about the Compound
Drug 1 ( Tyr-D-Phe-Gly-Trp-Nle-Asp-Phe-NH2 )
Drug Name Tyr-D-Phe-Gly-Trp-Nle-Asp-Phe-NH2
Target(s)
Opioid receptor delta (OPRD1)
Inhibitor
Cholecystokinin receptor type A (CCKAR)
Inhibitor
Opioid receptor mu (MOP)
Inhibitor
Gastrin/cholecystokinin type B receptor (CCKBR)
Inhibitor